Dantrolene improves left ventricular diastolic property in mineralcorticoid-salt-induced hypertensive rats.
Calmodulin
Dantrolene
HFpEF
Hypertrophy
Journal
Biochemistry and biophysics reports
ISSN: 2405-5808
Titre abrégé: Biochem Biophys Rep
Pays: Netherlands
ID NLM: 101660999
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
22
12
2022
revised:
13
02
2023
accepted:
26
02
2023
entrez:
17
3
2023
pubmed:
18
3
2023
medline:
18
3
2023
Statut:
epublish
Résumé
Left ventricular (LV) diastolic dysfunction is increasingly common in heart failure with preserved ejection fraction (HFpEF), and new drug therapy is desired. We recently reported that dantrolene (DAN) attenuates pressure-overload induced hypertrophic signaling through stabilization of tetrameric structure of cardiac ryanodine receptor (RyR2). Because cardiac hypertrophy substantially affects LV diastolic properties, we investigated the effect of DAN on LV diastolic properties in mineralocorticoid-salt-induced hypertensive rat model exhibiting the HFpEF phenotype. Male Sprague-Dawley (SD) rats (8 weeks old) received an uninephrectomy (UNX), subcutaneous implantation of a 200 mg pellet of deoxycorticosterone acetate (DOCA), and 0.9% NaCl water (UNX + DOCA-salt). UNX, a control pellet, and water without NaCl served as controls (UNX control). The effect of oral administration of 100 mg/kg/d DAN was examined in UNX control and UNX + DOCA-salt groups (UNX + DAN and UNX + DOCA-salt + DAN). UNX + DOCA-salt treatment resulted in mild hypertension. Chronic administration of DAN to UNX + DOCA-salt rats (UNX + DOCA-salt + DAN) did not affect blood pressure. DAN treatment increased the mitral annular early relaxation velocity in the UNX + DOCA-salt group. The size of cardiomyocytes increased in the UNX + DOCA-salt group, whereas the increase was suppressed by DAN treatment. LV fibrotic area was significantly smaller in the UNX + DOCA-salt + DAN group than in the UNX + DOCA-salt group (2.0 ± 0.2% vs 4.0 ± 0.4%). The LV chamber stiffness significantly increased in the UNX + DOCA-salt group, whereas the increase was suppressed by DAN treatment. DAN treatment normalized the CaM-RyR2 interaction and inhibited aberrant Ca
Identifiants
pubmed: 36926278
doi: 10.1016/j.bbrep.2023.101449
pii: S2405-5808(23)00030-4
pmc: PMC10011190
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101449Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Circ J. 2010 Nov;74(12):2579-84
pubmed: 20944434
J Mol Cell Cardiol. 2018 Dec;125:87-97
pubmed: 30359562
Circulation. 2018 Jul 3;138(1):12-24
pubmed: 29519849
Heart Rhythm. 2022 Jun;19(6):986-997
pubmed: 35134547
Cell Mol Life Sci. 2014 Feb;71(4):549-74
pubmed: 23649149
Circ J. 2011;75(4):823-33
pubmed: 21436596
Am J Physiol Cell Physiol. 2007 Sep;293(3):C1073-81
pubmed: 17376815
J Cardiovasc Pharmacol. 2021 Jun 1;77(6):822-829
pubmed: 34016843
Bio Protoc. 2020 Aug 05;10(15):e3708
pubmed: 33659372
Circ Res. 2010 Apr 30;106(8):1413-24
pubmed: 20224043
Circulation. 1996 Dec 15;94(12):3362-8
pubmed: 8989152
N Engl J Med. 2006 Jul 20;355(3):260-9
pubmed: 16855266
JCI Insight. 2019 Jun 6;4(11):
pubmed: 31167968
Cardiovasc Res. 2010 Sep 1;87(4):609-17
pubmed: 20388639
Circulation. 2021 Apr 13;143(15):1513-1525
pubmed: 33550817
Biochem J. 2012 May 15;444(1):105-14
pubmed: 22360269
Commun Biol. 2020 Nov 26;3(1):714
pubmed: 33244105
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
Am J Physiol Heart Circ Physiol. 2019 Nov 1;317(5):H877-H890
pubmed: 31441689